<DOC>
	<DOCNO>NCT01183312</DOCNO>
	<brief_summary>The term 'hypersomnia ' describes group symptom include severe daytime sleepiness sleep long period time ( 10 hour per night ) . Sometimes , hypersomnia cause problem quality sleep occur night , instance nighttime sleep disrupt frequent breathing pause . In case , however , hypersomnia occurs even nighttime sleep good quality . These case hypersomnia presumed symptom brain dysfunction , refer hypersomnias central ( i.e. , brain ) origin , primary hypersomnia . The cause primary hypersomnia know . However , group recently identify problem major brain chemical responsible sedation , know GABA . In subset hypersomnia patient , naturally-occurring substance cause GABA receptor hyperactive . In essence , though patient chronically medicate Valium ( Xanax alcohol , substance act GABA system ) , even though take medication . Current treatment central hypersomnia limit . For fraction case narcolepsy , FDA-approved , available treatment . However , remainder patient , treatment approve FDA . They usually treat medication approve narcolepsy , sleep expert agree medication often effective group patient . Based understanding GABA abnormality patient , evaluate whether flumazenil ( medication approve FDA treatment overdose GABA medication reversal GABA-based anesthesia ) would reverse GABA abnormality patient . In test tube model disease , flumazenil fact return function GABA system normal . The investigator treat patient flumazenil felt hypersomnia symptom improve treatment . To determine whether flumazenil truly beneficial primary hypersomnia , study compare flumazenil inactive pill ( placebo ) . All subject receive flumazenil placebo different time , reaction time symptom compare two treatment determine one superior . Currently , flumazenil give injection vein ( i.e. , intravenously ) . This study evaluate intravenous dose well new form flumazenil , take lozenge dissolve tongue . If study show flumazenil effective placebo treatment hypersomnia , identify potential new therapy difficult-to-treat disorder .</brief_summary>
	<brief_title>Flumazenil Treatment Primary Hypersomnia</brief_title>
	<detailed_description />
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Cataplexy</mesh_term>
	<mesh_term>Disorders Excessive Somnolence</mesh_term>
	<mesh_term>Hypersomnolence , Idiopathic</mesh_term>
	<mesh_term>Flumazenil</mesh_term>
	<criteria>Hypersomnia ( meet clinical criterion idiopathic hypersomnia without long sleep time , narcolepsy lack cataplexy , symptomatic hypersomnia meeting International Classification Sleep Disorders 2 ( ICSD2 ) criteria inclusive habitually long sleep period &gt; 10 hours/day ) evidence GABArelated abnormality , demonstrate inhouse , vitro assay age &gt; 18 high performance liquid chromatography/liquid chromatography tandem mass spectrometry verification absence exogenous benzodiazepine ( BZDs ) . Contraindications use flumazenil ( pregnancy , hepatic impairment , seizure history , premenstrual dysphoric disorder , traumatic brain injury , cardiac disease ( left ventricular diastolic dysfunction ) , cardiac dysrrhythmia . Current use BZD BZDreceptor agonists moderate severe sleep apnea ( RDI &gt; 15/hr ) , severe periodic limb movement disorder ( PLMI &gt; 30/hr ) diagnosis narcolepsy cataplexy , determine ICSD2 criterion confirm absence cerebrospinal fluid ( CSF ) hypocretin metabolic disorder severe anemia , adrenal insufficiency , severe iron deficiency , vitamin B12 deficiency , hypothyroidism may explain symptom hypersomnia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hypersomnia</keyword>
	<keyword>Primary Hypersomnia</keyword>
	<keyword>Idiopathic Hypersomnia</keyword>
	<keyword>Narcolepsy without Cataplexy</keyword>
	<keyword>Flumazenil</keyword>
</DOC>